Nevertheless, reaching sufficient levels of blocking antibodies for improved anti-tumor responses can be challenging, and the systemic antibody administration can lead to adverse events due to the pivotal role that the PD-1/PD-L1 pathway simultaneously plays in preventing autoimmunity [4,45]. Here, PDCD1 is linked to Autoimmunity.